8-K: Corvus Pharmaceuticals Announces Positive Interim Data for Soquelitinib in Atopic Dermatitis Trial

Corvus Pharmaceuticals reports encouraging interim results from a Phase 1 clinical trial of soquelitinib for atopic dermatitis, showing significant improvements compared to placebo.

Summary

• Corvus Pharmaceuticals has released interim data from a Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis.
• The trial included 16 patients in Cohort 1 and 10 patients in Cohort 2, with 28 days of treatment completed.
• In the soquelitinib groups, 26% of patients achieved an IGA score of 0 or 1, and 37% achieved a 75% reduction in EASI score (EASI 75).
• None of the patients in the placebo group achieved IGA 0 or 1 or EASI 75.
• The trial is evaluating different doses of soquelitinib, including 100 mg twice daily, 200 mg once daily, 200 mg twice daily, and 400 mg once daily.
• The primary endpoints of the trial are safety and tolerability, with efficacy as a secondary endpoint.
• Full results from all four study cohorts are expected in the second quarter of 2025.

Sentiment

Score: 8

Explanation: The document presents positive interim results for soquelitinib, with a favorable safety profile and efficacy signals. The management's comments are optimistic, and the company is moving forward with further trials. However, it is still early-stage data, and there are inherent risks in drug development.

Positives

• Soquelitinib demonstrated clinically meaningful activity in treating atopic dermatitis.
• The 200 mg once-daily dose in Cohort 2 appears to show better results than the initial 100 mg twice-daily dose in Cohort 1.
• The drug has a favorable safety profile with no significant safety issues or lab abnormalities reported.
• Soquelitinib is administered orally, which is convenient for patients.
• The drug has a novel mechanism of action, potentially making it an attractive treatment option.
• The company is also advancing a Phase 3 trial for soquelitinib in T-cell lymphoma.

Negatives

• The results are from an interim analysis and may change as the trial progresses.
• The study is still in Phase 1, and further trials are needed to confirm efficacy and safety.
• The trial has a small sample size, with only 26 patients completing 28 days of treatment across two cohorts.

Risks

• The company's ability to demonstrate sufficient efficacy and safety in clinical trials is not guaranteed.
• The results of preclinical studies and interim data may not be predictive of future results.
• The company may face challenges in enrolling sufficient patients in clinical trials.
• The regulatory process is unpredictable, and approvals are not guaranteed.
• Clinical trial costs may exceed expectations.
• The company may need to raise additional capital.

Future Outlook

The company plans to complete enrollment in the atopic dermatitis trial and report full results in the second quarter of 2025, while also continuing to advance their Phase 3 trial in peripheral T cell lymphoma and other clinical programs. They believe soquelitinib will be attractive to physicians and patients due to its convenient oral administration, safety and novel mechanism of action.

Management Comments

• Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus, stated that they are excited by the outlook for the Phase 1 clinical trial of soquelitinib for the treatment of atopic dermatitis.
• Dr. Miller noted that the data from Cohort 2 appears better than the initial results from Cohort 1.
• Dr. Miller believes soquelitinib will be attractive to physicians and patients due to its convenient oral administration, safety and novel mechanism of action.

Industry Context

The announcement is relevant to the broader pharmaceutical industry focused on developing new treatments for atopic dermatitis, a common chronic skin condition. The results position soquelitinib as a potential competitor to existing topical, oral, and injectable therapies. The focus on IGA 0 or 1 and EASI 75 as endpoints aligns with industry standards for clinical trials in this space.

Comparison to Industry Standards

• The use of IGA 0 or 1 and EASI 75 as primary endpoints is consistent with other clinical trials for atopic dermatitis treatments, such as those for Dupixent (dupilumab) by Sanofi and Regeneron, and Rinvoq (upadacitinib) by AbbVie.
• The reported efficacy of 26% achieving IGA 0 or 1 and 37% achieving EASI 75 in the soquelitinib group is promising, but further data is needed to compare it directly to the efficacy rates of approved treatments.
• For example, Dupixent has shown higher EASI 75 response rates in pivotal trials, but it is an injectable biologic, while soquelitinib is an oral small molecule, which may offer a different value proposition.
• Rinvoq, an oral JAK inhibitor, has also demonstrated high efficacy in atopic dermatitis, and soquelitinib will need to show comparable or superior results in future trials to gain market share.

Stakeholder Impact

• Shareholders may react positively to the encouraging interim data.
• Patients with atopic dermatitis may see soquelitinib as a potential new treatment option.
• Physicians may be interested in the drug's novel mechanism of action and oral administration.
• Employees of Corvus Pharmaceuticals may be motivated by the positive trial results.

Next Steps

• Complete enrollment in the atopic dermatitis Phase 1 clinical trial.
• Report full results from all four study cohorts in the second quarter of 2025.
• Continue to advance the Phase 3 registration trial of soquelitinib in peripheral T cell lymphoma.
• Continue to advance other clinical programs.

Key Dates

Keywords

soquelitinib, atopic dermatitis, clinical trial, EASI 75, IGA 0 or 1, ITK inhibitor, immunotherapy, eczema, Phase 1, Corvus Pharmaceuticals